{"organizations": [], "uuid": "d5ad6af29a2cf5a49e9f0f4d423d97e9dd9470cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.google.com/news?q=migraine&sourceid=navclient-ff&ie=UTF-8&rlz=1B3GGGL_enUS176__218&output=rss", "section_title": "migraine - Google News", "url": "https://www.reuters.com/article/brief-amgen-says-fda-approves-aimovig-a/brief-amgen-says-fda-approves-aimovig-a-treatment-for-migraine-prevention-idUSASC0A2VS", "country": "US", "domain_rank": 408, "title": "BRIEF-Amgen Says FDA Approves Aimovig, A Treatment For Migraine Prevention - Reuters", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-05-18T02:44:00.000+03:00", "replies_count": 0, "uuid": "d5ad6af29a2cf5a49e9f0f4d423d97e9dd9470cf"}, "author": "", "url": "https://www.reuters.com/article/brief-amgen-says-fda-approves-aimovig-a/brief-amgen-says-fda-approves-aimovig-a-treatment-for-migraine-prevention-idUSASC0A2VS", "ord_in_thread": 0, "title": "BRIEF-Amgen Says FDA Approves Aimovig, A Treatment For Migraine Prevention - Reuters", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "treatment for migraine prevention - reuters", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "migraine prevention reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 17 (Reuters) - Amgen Inc:\n* FDA APPROVES AIMOVIGâ„¢ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION\n* AIMOVIG IS EXPECTED TO BE AVAILABLE TO PATIENTS WITHIN ONE WEEK Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-05-18T02:44:00.000+03:00", "crawled": "2018-05-18T04:22:26.003+03:00", "highlightTitle": ""}